PD-L1 Expression is Related to Tumor Staging in NSCLC

被引：0
|
作者：
Wang, Hangjun
Agulnik, Jason [1 ,2 ]
Kasymjanova, Goulnar [3 ]
Wang, Anna Y. [1 ,2 ]
Cohen, Victor [1 ,2 ]
Small, David [1 ,2 ]
Pepe, Carmela [1 ,2 ]
Sakr, Lama [1 ,2 ]
Fiset, Pierre O. [4 ]
Auger, Manon
Camilleri-Broet, Sophie [2 ,4 ]
Alameldin, Mona [2 ,4 ]
Chong, George [2 ,4 ]
van Kempen, Leon [2 ,4 ]
Spatz, Alan [2 ,4 ]
机构：
[1] Jewish Gen Hosp, Montreal, PQ, Canada
[2] McGill Univ, Montreal, PQ, Canada
[3] JGH, Montreal, PQ, Canada
[4] McGill Univ, Hlth Ctr, Glen Site, Montreal, PQ, Canada
来源：
LABORATORY INVESTIGATION | 2018年 / 98卷
关键词：
D O I：
暂无
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
2114
引用
收藏
页码：755 / 755
页数：1
相关论文
共 50 条
  • [41] Heterogeneity of Tumor and Immune Cell PD-L1 Expression and Lymphocyte Counts in Surgical NSCLC Samples
    Casadevall, David
    Clave, Sergi
    Taus, Alvaro
    Hardy-Werbin, Max
    Rocha, Pedro
    Lorenzo, Marta
    Menendez, Silvia
    Salido, Marta
    Albanell, Joan
    Pijuan, Lara
    Arriola, Edurne
    CLINICAL LUNG CANCER, 2017, 18 (06) : 682 - +
  • [42] Sequential tracking of PD-L1 expression on circulating tumor cells in NSCLC patients treated with nivolumab
    Akamatsu, Hiroaki
    Koh, Yasuhiro
    Mori, Keita
    Kanai, Kuninobu
    Hayata, Atsushi
    Tokudome, Nahomi
    Higuchi, Masayuki
    Kanbara, Hlsashige
    Akamatsu, Keiichiro
    Nakanishi, Masanori
    Ueda, Hiroki
    Yamamoto, Nobuyuki
    MOLECULAR CANCER THERAPEUTICS, 2018, 17 (01)
  • [43] PD-L1 and Tumor Infiltrating Lymphocytes as Prognostic Markers in Resected NSCLC
    Ameratunga, Malaka
    Asadi, Khashayar
    Lin, Xihui
    Walkiewicz, Marzena
    Murone, Carmel
    Knight, Simon
    Mitchell, Paul
    Boutros, Paul
    John, Thomas
    PLOS ONE, 2016, 11 (04):
  • [44] Monitoring PD-L1 expression on circulating tumor cells (CTCs) in patients with NSCLC treated with PD1 inhibitors.
    Guibert, Nicolas Marie
    Delaunay, Myriam
    Lusque, Amellie
    Gouin, Sandrine
    Boubekeur, Nadia
    Rouquette, Isabelle
    Clermont, Estelle
    Fourtoul, Aurelien
    Favre, Gilles
    Pradines, Anne
    Mazieres, Julien
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (05)
  • [45] Correlation Between PD-L1 Gene Promoter Polymorphisms and Expression of PD-L1 mRNA and Protein in NSCLC Patients.
    Kucharczyk, T.
    Grenda, A.
    Krawczyk, P.
    Nicos, M.
    Jarosz, B.
    Szumilo, J.
    Reszka, K.
    Trojanowski, T.
    Milanowski, J.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S732 - S732
  • [46] Beyond PD-L1: Unraveling the enigma of immunotherapy response in PD-L1 negative (<1%) NSCLC patients through quantification of PD-1/PD-L1 engagement in the tumor microenvironment
    Gumuzio, Juan
    Calleja, Veronique
    Miles, James
    Sancehz-Magraner, Lissete
    Aguirre, Fernando
    MOLECULAR CANCER THERAPEUTICS, 2023, 22 (12)
  • [47] Immune profiling of in NSCLC shows expression of PD-L1 in macrophages is better associated with outcomes than PD-L1 in tumor cells in PD-1 axis immunotherapy treated patients
    Liu, Yuting
    Zugazagoitia, Jon
    Henick, Brian
    Schalper, Kurt A.
    Rimm, David L.
    CANCER RESEARCH, 2019, 79 (13)
  • [48] Assessment of PD-L1 Expression in Gastric Tumor Samples
    Scorer, P.
    Barker, C.
    Scott, M.
    Li, W.
    Rebelatto, M.
    Walker, J.
    JOURNAL OF MOLECULAR DIAGNOSTICS, 2020, 22 (11): : S61 - S61
  • [49] PD-1 and PD-L1 Expression in NSCLC Indicate a Favorable Prognosis in Defined Subgroups
    Schmidt, Lars Henning
    Kuemmel, Andreas
    Goerlich, Dennis
    Mohr, Michael
    Broeckling, Sebastian
    Mikesch, Jan Henrik
    Gruenewald, Inga
    Marra, Alessandro
    Schultheis, Anne M.
    Wardelmann, Eva
    Mueller-Tidow, Carsten
    Spieker, Tilmann
    Schliemann, Christoph
    Berdel, Wolfgang E.
    Wiewrodt, Rainer
    Hartmann, Wolfgang
    PLOS ONE, 2015, 10 (08):
  • [50] Efficacy of PD-1/PD-L1 Immune Checkpoint Inhibitors for Advanced NSCLC According to PD-L1 Expression: A Meta-Analysis
    Ma, K.
    Guo, Y.
    Wang, Y.
    Wang, X.
    Xu, Y.
    Sun, C.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S584 - S584
12345